Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Progenics Pharms Inc	PYLARIFY	piflufolastat f-18	SOLUTION;INTRAVENOUS	214793	NDA	Progenics Pharmaceuticals, Inc.	71258-022-01	50 mL in 1 VIAL, MULTI-DOSE (71258-022-01)	2021-05-26
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Pylarify, an FDA-approved radiopharmaceutical for PET imaging of prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC), relies on a complex and time-sensitive supply chain. Key components include the gallium-68 (⁶⁸Ga) radionuclide generator, the PSMA-targeting ligand, and the radiolabeling chemistry. Major suppliers are concentrated in North America and Europe, with increasing interest in diversified sourcing and potential domestic production capabilities.

Who are the primary suppliers for Pylarify's key components?

The supply chain for Pylarify involves multiple critical components, each with distinct sourcing requirements.

Gallium-68 Generators

The generation of the gallium-68 (⁶⁸Ga) radionuclide, essential for Pylarify, is primarily achieved through germanium-68 (⁶⁸Ge)/gallium-68 (⁶⁸Ga) radioisotope generators. These generators are sophisticated devices requiring specialized manufacturing and handling due to their radioactive nature.

ITM Medical GmbH (ITM): A leading provider of medical radioisotopes and radiopharmaceuticals, ITM is a significant supplier of ⁶⁸Ge/⁶⁸Ga generators. Their Galius® generator system is widely used in clinical settings. ITM operates manufacturing facilities in Germany and has a global distribution network.
Curium Pharma (formerly Mallinckrodt): Curium Pharma is another key player in the radiopharmaceutical market and offers ⁶⁸Ge/⁶⁸Ga generators. Their product is also integral to the supply of ⁶⁸Ga for diagnostic imaging agents. Curium has manufacturing sites in the United States and Europe.
Blue Earth Diagnostics: While primarily focused on radiotracer development and commercialization, Blue Earth Diagnostics is involved in the broader ecosystem of ⁶⁸Ga-based diagnostics and partners with generator manufacturers.

The supply of these generators is subject to regulatory oversight and requires adherence to strict quality control measures to ensure the purity and activity of the eluted ⁶⁸Ga. Lead times for generator acquisition and replacement are critical operational considerations.

PSMA-Targeting Ligands

The PSMA-targeting ligand, which binds to the PSMA expressed on prostate cancer cells, is a complex small molecule requiring sophisticated chemical synthesis. The synthesis often involves multiple steps and specialized reagents.

Contract Manufacturing Organizations (CMOs): The synthesis of the specific PSMA-targeting ligand for Pylarify is likely outsourced to specialized CMOs with expertise in complex organic synthesis and cGMP (current Good Manufacturing Practice) compliance. Identifying specific CMOs can be challenging due to confidentiality agreements. However, companies known for handling complex pharmaceutical ingredients include:
- Lonza: A global leader in pharmaceutical, biotech, and nutrition markets, Lonza provides contract development and manufacturing services for active pharmaceutical ingredients (APIs).
- Thermo Fisher Scientific (Patheon): Through its Patheon brand, Thermo Fisher offers a broad range of CDMO services, including API manufacturing for complex molecules.
- Catalent: Another major CDMO, Catalent provides integrated services for drug development and manufacturing, including API synthesis.

The sourcing of these ligands demands rigorous quality assurance to ensure isomeric purity, absence of residual solvents, and consistent batch-to-batch quality. The intellectual property surrounding the ligand synthesis can also influence supplier choice.

Radiolabeling Kits and Reagents

The final step in producing Pylarify involves the rapid and efficient radiolabeling of the PSMA-targeting ligand with ⁶⁸Ga. This process utilizes specific kits and reagents.

Navidea Biopharmaceuticals: Navidea developed and holds the intellectual property for PYLARTIL®, which is the radiolabeling kit component used to produce Pylarify. Therefore, Navidea is the direct or indirect supplier of this critical reagent set.
Specialty Chemical Suppliers: The components within the radiolabeling kits themselves may be sourced from various specialty chemical suppliers. These could include companies providing specific chelating agents, buffers, and other biochemicals necessary for the radiolabeling reaction. Examples of such suppliers include:
- Sigma-Aldrich (now part of Merck KGaA): A vast supplier of laboratory chemicals and biochemicals.
- VWR International (Avantor): Provides a broad range of laboratory products and services.

The availability and quality of these reagents are paramount for successful and timely radiolabeling at the point of care or at radiopharmacies.

What is the geographic distribution of key suppliers?

The primary suppliers for Pylarify's components are geographically concentrated, predominantly in North America and Europe. This concentration presents both advantages in terms of established infrastructure and potential risks related to supply chain disruptions.

Europe: Germany is a notable hub for ⁶⁸Ge/⁶⁸Ga generator manufacturing, with companies like ITM Medical GmbH based there. Several major CMOs with API synthesis capabilities also operate extensively in European countries such as Switzerland, Germany, and Ireland.
North America: The United States hosts significant radiopharmaceutical companies and numerous CMOs capable of complex API synthesis. Curium Pharma has a strong presence in the US for generator supply.

This geographic concentration necessitates robust logistical planning for the timely delivery of components, especially the time-sensitive ⁶⁸Ga generators.

What are the regulatory considerations impacting the supply chain?

The pharmaceutical supply chain, particularly for radiopharmaceuticals, is heavily regulated to ensure patient safety and product efficacy.

FDA Regulations: In the United States, the Food and Drug Administration (FDA) oversees the manufacturing, quality, and distribution of drugs and radiopharmaceuticals. Suppliers of APIs, finished drug products, and critical components like radionuclide generators must adhere to cGMP standards. Facility inspections and rigorous documentation are mandatory.
International Regulations: Similar regulatory bodies exist in other regions, such as the European Medicines Agency (EMA) in Europe. Harmonization of international standards is ongoing but regional differences in regulatory interpretation can impact global supply chains.
Transportation of Radioactive Materials: The transport of ⁶⁸Ge/⁶⁸Ga generators is governed by strict regulations from bodies like the Department of Transportation (DOT) in the US and international bodies such as the International Atomic Energy Agency (IAEA). These regulations dictate packaging, labeling, and transport procedures to ensure safety.
DEA Oversight: While Pylarify itself is not a controlled substance, the sourcing of certain precursors or the handling of materials within the synthesis process might fall under specific Drug Enforcement Administration (DEA) or equivalent international agency purview if they are listed chemicals.

Compliance with these regulations is non-negotiable and requires significant investment in quality systems and personnel.

What are the key challenges and risks in the Pylarify supply chain?

The Pylarify supply chain faces several inherent challenges and risks that require proactive management.

Short Half-Life of ⁶⁸Ga: Gallium-68 has a half-life of approximately 68 minutes. This necessitates on-demand generation and immediate use, creating significant logistical pressure for both generator delivery and subsequent radiolabeling. Delays in any part of the chain can lead to wasted product and patient care disruptions.
Limited Number of ⁶⁸Ge/⁶⁸Ga Generator Suppliers: The specialized nature of ⁶⁸Ge/⁶⁸Ge generator manufacturing means there are a limited number of qualified suppliers globally. This can create dependency and vulnerability to supply disruptions from a single source.
Complexity of API Synthesis: The PSMA-targeting ligand is a complex molecule requiring multi-step synthesis. This increases the risk of production issues, quality deviations, and extended lead times from CMOs. Batch failures can have substantial impacts on product availability.
Radiopharmaceutical Manufacturing Expertise: The final radiolabeling process requires specialized facilities and highly trained personnel, often found in nuclear pharmacies or centralized radiopharmacies. A shortage of such facilities or trained staff can limit the reach of Pylarify.
Geopolitical and Economic Factors: Global supply chains are susceptible to geopolitical instability, trade disputes, and economic downturns, which can affect the availability and cost of raw materials and components.
Regulatory Changes: Evolving regulatory requirements or unexpected inspections can lead to temporary halts in production or the need for significant process adjustments.

What are potential strategies to mitigate supply chain risks?

Several strategies can be employed to enhance the resilience of the Pylarify supply chain.

Supplier Diversification: Actively seeking and qualifying secondary suppliers for critical components, including radionuclide generators and key intermediates for API synthesis, can reduce reliance on single sources.
Inventory Management and Strategic Stockpiling: While challenging for short-lived radionuclides, strategic stockpiling of long-lead-time components or stable intermediates for API synthesis can provide a buffer against short-term disruptions. For generators, maintaining adequate on-site inventory at larger radiopharmacies may be feasible.
Investments in Domestic Manufacturing Capabilities: Supporting or investing in domestic manufacturing for radionuclide generators and APIs can reduce reliance on international supply chains and mitigate risks associated with global logistics and trade policies.
Enhanced Collaboration and Information Sharing: Closer collaboration with key suppliers and contract manufacturers, including robust demand forecasting and transparency regarding production schedules, can improve predictability and responsiveness.
Technological Advancement: Exploring next-generation radiolabeling technologies or alternative radionuclide sources could eventually de-risk the supply chain by moving away from the current reliance on ⁶⁸Ga generators.
Contingency Planning and Business Continuity: Developing comprehensive contingency plans for various disruption scenarios (e.g., natural disasters, regulatory actions, supplier failures) with defined mitigation steps is crucial.

Key Takeaways

Pylarify's supply chain is complex, involving specialized suppliers for gallium-68 generators, PSMA-targeting ligands, and radiolabeling kits.
Key suppliers are concentrated in North America and Europe, presenting logistical challenges due to the short half-life of ⁶⁸Ga.
Strict regulatory oversight from agencies like the FDA and EMA governs manufacturing, quality, and transportation.
Significant risks include the short half-life of ⁶⁸Ga, limited generator suppliers, complex API synthesis, and global supply chain vulnerabilities.
Mitigation strategies focus on supplier diversification, strategic inventory, domestic manufacturing support, and enhanced collaboration.

Frequently Asked Questions

How does the short half-life of gallium-68 impact Pylarify's distribution and clinical use? The 68-minute half-life of ⁶⁸Ga necessitates that Pylarify be produced on-demand at or near the point of administration. This requires a highly synchronized supply chain, from generator delivery to radiolabeling and patient injection, limiting its reach to facilities with the necessary infrastructure and trained personnel for on-site radiopharmaceutical production.
Are there any alternative radionuclide sources being explored for PSMA-targeting therapies that could alleviate reliance on germanium-68 generators? Research is ongoing into other positron-emitting radionuclides for PSMA imaging, such as Copper-64 (⁶⁴Cu) and Fluorine-18 (¹⁸F), which can be produced in cyclotrons. These alternatives offer different half-lives and production methods that could potentially diversify the supply chain and expand access.
What are the primary quality control measures employed to ensure the purity and efficacy of Pylarify? Quality control involves rigorous testing at multiple stages: verification of the radionuclide's purity and activity from the generator, validation of the PSMA-targeting ligand's synthesis for chemical purity and identity, and confirmation of successful radiolabeling, including radiochemical purity and stability of the final Pylarify product before administration.
What is the role of contract manufacturing organizations (CMOs) in the Pylarify supply chain? CMOs are critical for the synthesis of the complex PSMA-targeting ligand, which forms the inactive part of Pylarify. These organizations must operate under strict cGMP regulations to produce the active pharmaceutical ingredient (API) consistently and to the required purity standards.
How do global trade policies and geopolitical events potentially affect the availability of Pylarify components? Geopolitical events can disrupt international shipping routes, impose tariffs, or restrict the export of critical raw materials or finished components. Trade policies can influence the cost and accessibility of chemicals and specialized equipment needed for Pylarify's production, potentially leading to shortages or price increases.

Citations

[1] ITM Medical GmbH. (n.d.). Galius®. Retrieved from https://www.itm-medical.com/products/gallium-68-generators/galius/

[2] Navidea Biopharmaceuticals. (n.d.). PYLARTIL®. Retrieved from https://www.navidea.com/pipeline/pylarify/

[3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

[4] International Atomic Energy Agency. (n.d.). Regulations for the Safe Transport of Radioactive Material. Retrieved from https://www.iaea.org/resources/publications/safety/transport-radioactive-material

Suppliers and packagers for PYLARIFY

PYLARIFY

Pylarify Supply Chain Analysis